SCHEMBL30674686

SCHEMBL30674686

CCOC(=O)C1C(=O)CN(C(=O)OC(C)(C)C)[C@@H]1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
MAPT P10636 2/20 0.38
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 6/20 0.36
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
TSHR P16473 1/20 0.36
GLA P06280 1/20 0.35
ALOX12 P18054 1/20 0.35
ADORA1 P30542 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2797179 1.00 NFKB1 (0.40) NFKB1NFKB2RELAMAPTMAPK1
SCHEMBL28000905 0.87 NFKB1 (0.38) NFKB1NFKB2RELAMAPTMAPK1
SCHEMBL24275820 0.79 MAPT (0.42) NFKB1NFKB2RELAMAPTMAPK1
SCHEMBL22620447 0.78 MAPT (0.41) NFKB1NFKB2RELAMAPTALDH1A1
SCHEMBL1326298 0.77 NFKB1 (0.40) NFKB1NFKB2RELAMAPTMAPK1
SCHEMBL2350221 0.75 NFKB1 (0.38) NFKB1NFKB2RELAMAPTALDH1A1
SCHEMBL14299247 0.75 MAPT (0.40) NFKB1NFKB2RELAMAPTMAPK1
SCHEMBL8273056 0.75 PTPN1 (0.41) NFKB1NFKB2RELAMAPTALDH1A1
SCHEMBL9273462 0.75 PTPN1 (0.41) NFKB1NFKB2RELAMAPTALDH1A1
SCHEMBL31603663 0.75 MEN1 (0.42) NFKB1NFKB2RELAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320227-A1 MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF JAZZ PHARMACEUTICALS IRELAND LTD (IE) 2025-10-16 US disclosed
EP-4532497-A1 MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF Jazz Pharmaceuticals Ireland Limited (IE) 2025-04-09 EP disclosed
CN-119630664-A Macrocyclic orexin receptor agonists and uses thereof 爵士制药爱尔兰有限公司 2025-03-14 CN disclosed
WO-2023232966-A1 MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2023-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320227-A1 MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF HCRTR1, HCRTR2, NPY1R NFKB1 3725/4885NFKB2 3589/4885RELA 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.